SLC5A2 and type 2 diabetes mellitus: In another retrospective cohort analysis of individuals with T2DM in Hong Kong, SGLT2 inhibitor use was linked with a decreased incidence of incident obstructive airway disease (OAD) and a lower rate of OAD exacerbations in clinical settings compared to DPP-4 inhibitors use.